Option deal gives Isis more control in Biogen SMA drug pact
This article was originally published in Scrip
Executive Summary
Investors appeared somewhat hesitant on 4 January about a new deal between Isis Pharmaceuticals and Biogen Idec, in which the latter company is paying the former $29 million up front for an option to later license ISIS-SMNRx, a Phase I stage drug under investigation to treat spinal muscular atrophy (SMA), a genetic neuromuscular disease.